IRCT20240701062299N1招募中3 期
Efficacy and Safety of Ticagrelor Monotherapy Compared to Dual Antiplatelet Therapy in Patients With Chronic Coronary Syndrome After Percutaneous Coronary Intervention
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 5,400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20 years 至 no limit（—）
- 性别
- All
入选标准
- •Male or female above 20 years of age undergoing PCI with a drug-eluting stent for treating chronic coronary syndrome.
- •The patient has provided written informed consent as approved by the ethics committee.
排除标准
- •Contraindication to aspirin, clopidogrel, ticagrelor, or any other reason that study drug should not be administered (including hypersensitivity, moderate or severe liver disease, active bleeding, and major surgery within 30 days)
- •Atrial fibrillation or other indication for oral anticoagulant therapy.
- •Concomitant oral or IV therapy with strong CYP3A inhibitors, CYP3A substrates with narrow therapeutic indices (cyclosporine, and quinidine), or strong CYP3A inducers (rifampin, rifampicin, phenytoin, and carbamazepine)
- •Females of child-bearing age unless negative pregnancy test at screening and willing to use effective contraception for the duration of trial
- •Females who are breastfeeding at the time of enrolment.
- •Previous PCI in the last 6 months.
- •Current (same hospitalization) or previous (within 12 months) acute coronary syndrome.
- •History of definite stent thrombosis.
- •Concomitant cardiac valve disease requiring invasive therapy.
- •Patients with acute heart failure, active myocarditis, or cardiomyopathy.
- •Patient in hemodialysis.
- •History of stroke or transient ischemic cerebrovascular accident.
- •History of intracranial hemorrhage or other intracranial pathology associated with increased bleeding risk.
- •Hemoglobin <10 g/dL
- •Peptic ulceration documented by endoscopy within the last 3 months unless healing proven by repeat endoscopy.
- •Any other condition deemed by the investigator to place the patient at excessive risk of bleeding with ticagrelor.
- •Participation in another trial with an investigational drug or device.
- •Assessment that the subject is not likely to comply with the study procedures or have complete follow-up.
- •Known drug or alcohol dependence within the past 12 months as judged by the investigator.
- •Patients with planned surgical intervention to treat any cardiac or non-cardiac condition.
- •Unsuccessful PCI or PCI without optimal stent placement; this decision is made by the supervising interventional cardiologist.
研究者
相似试验
招募中
不适用
The safety of ticagrelor monotherapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction and the effect on intramyocardial haemorrhageST-elevation myocardial infarctionheart attack10011082NL-OMON56396Academisch Medisch Centrum200
招募中
不适用
Ticagrelor monotherapy in PAtients treated with new-generation drug-eluting Stents for acute coronary Syndrome; T-PASS trialDiseases of the circulatory systemKCT0003744Yonsei University Health System, Severance Hospital2,850
已完成
不适用
Effect of ticagrelor versus clopidogrel plus aspirin in aging patients with unstable angina after elective percutaneous coronary interventioUnstable anginaISRCTN13088814First People's Hospital of Taicang196
招募中
不适用
SETiP-ACS Randomized Clinical TrialKCT0007982Korea University Anam Hospital2,600
招募中
3 期
Effects of Ticagrelor on the Clinical consequences of Angioplasty in Myocardial Infarction and Covid-19.dIRCT20220813055675N1Artesh University of Medical Sciences200